evipedia.ai
← Back

Melanotan II for Health & Longevity

Evidence Review created on 10/26/2026 using AI4L / Opus 5.5

Also known as: MT-II, MTII, MT2, Melanotan 2, Melanotan-II

Motivation

Melanotan II is a lab-made, injectable copy of a natural hormone that tells the skin’s pigment cells to make melanin, the brown-black pigment behind a tan. Because it also reaches the brain, it has been studied for effects on sexual arousal and appetite. It interests people who want a tan without sun exposure, a stronger libido, or less hunger, and who are willing to self-inject an unapproved compound to get them.

The compound was designed at a university in the 1990s as a possible way to lower skin cancer risk by tanning the skin without sunlight. Early volunteer studies looked at sexual function as well as skin, and research later moved to a related drug. Melanotan II itself was never approved, yet it spread widely through online sellers, gyms, and tanning salons, and dermatologists began publishing reports on its users.

This review examines what direct and indirect human evidence shows about Melanotan II’s effects on skin, sexual function, and appetite, the harms reported with its use, and the quality of the products sold, for health-focused adults weighing it within a longevity frame.

Benefits - Risks - Protocol - Conclusion

This section lists expert commentary and narrative reviews that discuss Melanotan II in depth.

Content from Rhonda Patrick, Chris Kresser, Life Extension and Lifespan.io was not found: their site searches returned no material on Melanotan II (Life Extension’s search could not be rendered, and web searches found no article), likely because the compound is an unapproved injectable drug outside their usual scope.

Grokipedia

Melanotan II

An AI-generated encyclopedia entry covering Melanotan II’s chemistry, receptor pharmacology, investigated uses, clinical history, adverse effects and legal status; useful for orientation, not as primary evidence.

Examine

No Examine article on Melanotan II exists. Examine.com covers dietary supplements and does not typically cover unapproved injectable drugs such as Melanotan II.

ConsumerLab

No ConsumerLab article on Melanotan II exists; the site’s only search hit is a recall notice for unrelated eye drops. ConsumerLab does not typically cover unapproved injectable drugs such as Melanotan II.

Systematic Reviews

This section lists systematic reviews that cover Melanotan II’s effects and harms.

Fani 2014 represents the appetite and weight claim, mostly with animal data; no systematic review or meta-analysis has examined Melanotan II’s tanning or erectile effects as a primary outcome.

Mechanism of Action

Melanotan II is a cyclic seven-amino-acid peptide built from the active core of α-MSH (alpha-melanocyte-stimulating hormone, the body’s signal for pigment production), locked into a ring by a lactam bridge (a chemical link that resists enzyme breakdown) (Dorr 1996). Human data come almost entirely from its patent-holding University of Arizona inventors, a financial conflict of interest (Hadley 2006).

  • Receptor targets: It is a non-selective agonist (activator) of melanocortin receptors (cell-surface receptors for α-MSH-type hormones) (Wessells 2000).
  • Pigmentation: On melanocytes (skin pigment cells), activation of MC1R (melanocortin 1 receptor) raises melanin output.
  • Brain and spinal effects: Brain targets include MC4R (melanocortin 4 receptor, a brain receptor for appetite, sexual function and fight-or-flight (sympathetic) nervous activity). In rats, melanocortin receptors in the brain and spinal cord, not the penis, drive its erections (Wessells 2003), and brain infusion lowers food intake (Zhang 2010).
  • Competing interpretations: More melanin may shield skin from ultraviolet damage, as a related analogue showed in a trial co-authored by its developer, EpiTan (now Clinuvel) (Barnetson 2006); the same signal may also drive mole-cell growth in predisposed people (Cardones 2009).
  • Pharmacology: No human half-life (blood-level halving time) is published; rat blood levels decline in two phases (Ugwu 1994) and oral bioavailability (share of a swallowed dose absorbed) in rats is 4.6% (Lan 1994). Its metabolism is uncharacterized; analogue bremelanotide has a 2.7-hour half-life and is cleared by peptide-bond hydrolysis (enzymatic splitting) (Vyleesi label). In mice, only low levels reach the brain (Hatziieremia 2007).

Historical Context & Evolution

  • Original purpose: In the 1980s and 1990s, University of Arizona researchers designed potent α-MSH analogues to tan skin without ultraviolet exposure, framing Melanotan II as a “potential skin cancer chemopreventive peptide” (Lan 1994).
  • Unexpected finding: A three-man pilot confirmed tanning but also produced spontaneous erections, yawning and nausea (Dorr 1996), redirecting research to erectile dysfunction trials (Wessells 1998).
  • Commercial branching: The linear sibling Melanotan I became afamelanotide, authorised in the EU for a light-sensitivity disorder (European Medicines Agency Scenesse page); Melanotan II’s analogue bremelanotide became an approved treatment for low sexual desire in premenopausal women (Vyleesi label). Melanotan II itself was not developed further, its inventors’ review reports (Hadley 2006).
  • Path into health optimization: From the late 2000s, unregulated vials spread through websites, gyms and tanning salons as a “tanning jab,” valued for tanning, libido and appetite effects, a BMJ editorial reports (Evans-Brown 2009), and later joined a wider “biohacking” peptide trend described in a 2026 review (Moiz 2026).
  • How opinion shifted: The early skin-cancer-prevention rationale was never tested in Melanotan II trials. What changed was the arrival of case reports of new atypical moles and melanoma in users from 2009 onward, compiled in a dermatology review (Habbema 2017), alongside controlled photoprotection data for afamelanotide; neither line settles the question for Melanotan II.

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: every controlled Melanotan II trial comes from one University of Arizona research group, and all other support is indirect evidence from related compounds or animal studies.

Medium 🟩 🟩

Erectile Response & Sexual Desire in Men with Erectile Dysfunction

Melanotan II triggers erections without sexual stimulation by acting on brain and spinal melanocortin receptors. Two small double-blind, placebo-controlled crossover trials (each man received both drug and placebo) by the developer group found erections in 8 of 10 men with psychogenic (no physical cause) erectile dysfunction (Wessells 1998) and in men with organic (physical) risk factors, with higher sexual desire (Wessells 2000). Only single doses in about 20 men were tested, with no comparison against approved erectile dysfunction medications.

Magnitude: Psychogenic dysfunction: 38.0 vs 3.0 minutes of more than 80% tip rigidity (penile-tip firmness measured by a monitoring device) with placebo, 35.0 minutes more than placebo (Wessells 1998); organic risk factors: 45.3 vs 1.9 minutes, 43.4 minutes more than placebo (Wessells 2000); increased desire after 68% of Melanotan II doses vs 19% of placebo doses, 49 percentage points more than placebo (Wessells 2000); no 95% confidence interval (range likely to contain the true value) reported.

Low 🟩

Skin Pigmentation (Tanning) ⭕️ Not Central to Health & Longevity

Melanotan II darkens skin by stimulating melanin production in pigment cells. In a three-man pilot, two showed increased face and body pigmentation by reflectance (a light-based skin-color measurement) one week after five low doses (Dorr 1996). This bears on cosmetic appearance, not on health or lifespan.

Magnitude: Increased pigmentation in 2 of 3 men one week after dosing ended (no control group); the source reports no reflectance effect size.

Ultraviolet Photoprotection (Sunburn & DNA Damage)

Induced melanin may shield skin from ultraviolet (UV) injury. No Melanotan II study measured this; evidence is indirect, from the related compound afamelanotide, which reduced sunburn cells and DNA damage (Barnetson 2006) and lengthened pain-free sun exposure in a light-sensitivity disorder (Clinuvel-funded; Langendonk 2015).

Magnitude: Afamelanotide, not Melanotan II: median (middle value) pain-free direct sunlight 69.4 hours vs 40.8 hours with placebo over 6 months (U.S. trial, P=0.04; P is the probability the difference arose by chance), and 6.0 hours vs 0.8 hours with placebo (EU trial, P=0.005) (Langendonk 2015); the source reports group medians only, with no between-group difference or 95% confidence interval.

Appetite & Body-Weight Reduction

MC4R activation reduces food intake. Melanotan II trials noted decreased appetite only as a side effect (Wessells 1998); weight evidence is indirect, from setmelanotide, a different MC4R agonist used in rare genetic obesity (Rhythm-funded; Clément 2020), and a company-reported trial of bremelanotide added to tirzepatide (Palatin press release).

Magnitude: Setmelanotide, not Melanotan II: at least 10% weight loss at about 1 year in 8 of 10 participants with POMC (pro-opiomelanocortin, the hormone precursor) deficiency and 5 of 11 with LEPR (leptin receptor, the gene for the receptor that senses the fullness hormone leptin) deficiency (no control group) (Clément 2020).

Speculative 🟨

Brain Inflammation & Amyloid Reduction

In an Alzheimer’s mouse model, brain infusion of a Melanotan II analogue reduced amyloid (protein clumps linked to Alzheimer’s disease) deposits and glial (brain support-cell) inflammation (Lau 2021). The basis is animal data only.

Benefit-Modifying Factors

  • MC1R gene variants: With afamelanotide (indirect evidence), melanin rose more in carriers of MC1R variants, the fair-skinned group most prone to sunburn (developer EpiTan co-authored; Fitzgerald 2006); no Melanotan II genotype data exist.
  • Baseline skin pigmentation: With afamelanotide, melanin rose 41% in the most sun-sensitive skin vs 12% in less sensitive skin (Barnetson 2006), so pale baseline skin predicts a larger visible change.
  • Cause of erectile dysfunction: Erections occurred in both psychogenic and organic dysfunction (Wessells 2000); no data exist for men who fail approved erectile dysfunction medications.
  • Sex: All Melanotan II efficacy data are from men. Female desire evidence comes only from bremelanotide in premenopausal women (Palatin-funded; Kingsberg 2019).
  • Melanocortin pathway defects: Weight loss with MC4R agonism was shown in trials enrolling only people with rare POMC or LEPR deficiency (Clément 2020); effects in common obesity are unproven.
  • Age: No trial enrolled older adults; whether pigment and erectile responses persist with aging skin and blood vessels is unknown.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: Melanotan II’s controlled adverse-event data come from small trials by one research group, and its serious harms rest on case reports.

Medium 🟥 🟥

Nausea, Yawning & Drowsiness

These acute effects reflect melanocortin activation in brain and gut and appear within hours of injection. In the developer group’s trials, nausea and a stretching-yawning complex occurred more often than with placebo; somnolence (sleepiness) and fatigue appeared at 0.03 mg/kg (Dorr 1996), and severe nausea followed 4 of 19 injections at 0.025 mg/kg (Wessells 2000). Effects were transient and none required treatment (Wessells 1998).

Magnitude: Severe nausea after 4 of 19 Melanotan II injections at 0.025 mg/kg; the source does not report the placebo rate (Wessells 2000).

Low 🟥

Melanoma & Atypical Nevi

Melanotan II stimulates pigment cells inside moles. Case reports describe eruptive and atypical nevi (new moles with abnormal cell features) and darkening of existing moles (Cardones 2009, Reid 2013), and melanomas arising during or after use (Hjuler 2014, Ong 2012); causality is unproven.

Magnitude: Not quantified in available studies. Only case reports and case compilations exist, so no incidence or risk figure can be derived.

Priapism

Melanotan II’s centrally triggered erections can become ischemic priapism (a painful erection lasting hours that starves penile tissue of oxygen). Case reports describe emergency aspiration, phenylephrine injection, surgical decompression, and unrecovered erectile function at 4 weeks (Dreyer 2019, Mallory 2021).

Magnitude: Not quantified in available studies. Only case reports exist, without a count of exposed users.

Sympathomimetic (Adrenaline-Like) Toxicity, Rhabdomyolysis & Kidney Injury

After a 6 mg self-injection, one man developed tachycardia (fast heart rate), agitation, rhabdomyolysis with creatine kinase (a muscle-damage enzyme) peaking at 17,773 IU/L (international units per liter), and kidney dysfunction (Nelson 2012). Renal infarction has also been attributed to Melanotan II (Peters 2020). Both are single case reports.

Magnitude: Not quantified in available studies. Evidence consists of single case reports without a denominator.

Blood Pressure Rise & Posterior Reversible Encephalopathy Syndrome

MC4R activation raises blood pressure; for the analogue bremelanotide, a Palatin-sponsored trial found small transient rises (White 2017), and its label bars uncontrolled hypertension (Vyleesi label). Posterior reversible encephalopathy syndrome (brain swelling with headache, seizures, visual loss) followed melanotan use in one case (Kaski 2013).

Magnitude: Bremelanotide, not Melanotan II: ambulatory (portable round-the-clock monitoring) systolic (upper-number) blood pressure 3.1 to 3.2 mmHg higher than placebo 0 to 4 hours after 1.75 mg doses (White 2017); no Melanotan II figure exists.

Uneven, Persistent Hyperpigmentation

Melanocortin agonists can darken face, lips, gums and freckles unevenly; one user developed new lentigines (flat dark spots) after more than 150 doses (Thestrup-Pedersen 2011). For bremelanotide, focal darkening rose with daily dosing and did not always resolve (Vyleesi label).

Magnitude: Bremelanotide, not Melanotan II: focal hyperpigmentation in 1% with up to 8 doses per month vs 0% with placebo, and 38% after 8 consecutive daily doses (no control group) (Vyleesi label).

Injection-Site Pyoderma Gangrenosum

One woman developed pyoderma gangrenosum (an immune-driven skin disorder causing rapidly enlarging ulcers) at four abdominal melanotan injection sites; the ulcers resisted antibiotics, needed months of steroid treatment and healed with scarring (Dickson 2025). The report does not state whether the product was Melanotan I or II.

Magnitude: Not quantified in available studies. Only a single case report exists, without a count of exposed users.

Speculative 🟨

Contaminated, Mis-Dosed & Immunogenic Products

Vials held 4.32 to 8.84 mg against a labeled 10 mg, plus impurities (Breindahl 2015); the U.S. Food and Drug Administration (FDA) flags immunogenicity (immune reactions) (FDA Category 2 page). No human outcome data exist.

Risk-Modifying Factors

  • MC1R variants and fair skin: Red-hair MC1R variants already raise melanoma risk, and with afamelanotide these carriers showed the strongest melanin response (Fitzgerald 2006), concentrating pigment stimulation in the most vulnerable skin.
  • Melanoma or atypical-mole history: Atypical mole eruptions were reported in a man with prior melanoma and dysplastic (atypical) nevi (Cardones 2009) and in a teenager with FAMMM syndrome (inherited multiple atypical moles and melanoma) (Sivyer 2012).
  • Baseline blood pressure and mole count: Bremelanotide’s transient pressor (blood-pressure-raising) rises were measured only in women with normal or controlled high blood pressure (White 2017), so effects on top of uncontrolled hypertension are untested; a high baseline mole count obscures new or changing lesions.
  • Sex: Priapism is a male-specific risk (Dreyer 2019). Women lack Melanotan II pregnancy data; bremelanotide’s label requires contraception and stopping if pregnancy is suspected (Vyleesi label).
  • Darker skin: Bremelanotide’s label reports higher focal hyperpigmentation risk in darker skin (Vyleesi label).
  • Cardiovascular and kidney disease: Bremelanotide is contraindicated in uncontrolled hypertension or known cardiovascular disease (Vyleesi label); kidney injury appears in case reports (Peters 2020); greater danger with reduced kidney reserve is inferred, not studied.
  • Concurrent sunbed use: A melanoma case combined Melanotan II with sunbeds (Hjuler 2014), and forum users commonly pair both (Gilhooley 2021).
  • Older age: No older adults were studied; rising age-related melanoma and cardiovascular risk suggests greater absolute harm (inferred).

Key Interactions & Contraindications

Documented interactions:

  • None identified

Theoretical interactions (inferred from mechanism, not studied in humans):

  • Oral naltrexone: Inferred from slowed gastric emptying, as with the close analogue bremelanotide, whose label reports significantly lower oral naltrexone exposure, risking loss of alcohol- or opioid-dependence treatment effect (Vyleesi label); Avoid. Not tested with Melanotan II.
  • Oral medications needing reliable absorption: Inferred from bremelanotide’s slowing of gastric emptying, which can reduce absorption of threshold-dependent oral drugs such as antibiotics (amoxicillin, doxycycline); its label advises avoiding co-use (Vyleesi label). Not tested with Melanotan II.
  • Indomethacin: Inferred from slowed gastric emptying; in a safety review of bremelanotide’s Palatin-supported clinical program, co-administration lowered indomethacin plasma concentrations, possibly weakening pain relief (Clayton 2022); stopping the melanocortin agonist if pain relief is delayed mitigates this. Not tested with Melanotan II.
  • PDE5 inhibitors (sildenafil, tadalafil, vardenafil): Phosphodiesterase-5 inhibitors (erectile dysfunction medications that boost penile blood flow) add a peripheral erection signal to Melanotan II’s central one, raising priapism risk; avoiding same-day use mitigates this.
  • Other priapism-associated drugs (trazodone, intracavernosal (injected into the penis) alprostadil, papaverine): Additive erection-prolonging effects inferred from shared priapism risk; separating use and seeking care for erections lasting over 4 hours mitigates this.
  • Sympathomimetics, including over-the-counter decongestants (pseudoephedrine, phenylephrine), amphetamines (dextroamphetamine) and high-dose caffeine: Additive sympathetic activation could worsen blood pressure, heart rate and agitation, as in the Melanotan II toxicity case (Nelson 2012); avoiding co-use mitigates this.
  • Antihypertensives (amlodipine, lisinopril, losartan): Melanocortin-driven pressor effects may offset blood pressure control; home readings after dosing mitigate this.
  • GLP-1 (glucagon-like peptide-1) receptor agonists (semaglutide, tirzepatide): These appetite-suppressing drugs share nausea, appetite suppression and slowed gastric emptying, so effects may add; starting at the lowest dose mitigates this.
  • Other melanocortin agonists (bremelanotide, afamelanotide, setmelanotide): Overlapping receptor activation adds pigmentation, nausea and blood pressure effects; avoiding combined use mitigates this.
  • Yohimbine (supplement): Its stimulant action (blocking a brake on adrenaline release) adds blood pressure, heart rate and erectile effects; avoiding co-use mitigates this.
  • Forskolin (supplement): A systematic review reports it stimulates melanin independently of melanocortin receptors (Resnick 2026), so pigmentation and mole stimulation may add; avoiding co-use mitigates this.
  • Sunbeds and deliberate UV exposure (other intervention): UV and Melanotan II both stimulate pigment cells, plausibly compounding mole and melanoma risk; avoiding sunbeds mitigates this.

Populations who should avoid Melanotan II:

  • People with prior melanoma, dysplastic nevus syndrome or FAMMM syndrome: Case reports show amplified atypical mole growth in these groups (Cardones 2009, Sivyer 2012); the FDA notes reported melanoma (FDA Category 2 page).
  • People with uncontrolled hypertension or known cardiovascular disease: Contraindicated for the analogue bremelanotide (Vyleesi label); inferred for Melanotan II from shared MC4R pressor effects.
  • Pregnant or breastfeeding women and those trying to conceive: Inferred from fetal harm in animal studies of the analogue bremelanotide, whose label requires stopping if pregnancy is suspected (Vyleesi label); no human data for Melanotan II.
  • Men with prior priapism or sickle cell disease: Inferred from Melanotan II priapism case reports (Mallory 2021) and the known priapism tendency of these conditions; no human data in these groups.
  • People with kidney disease: Inferred from rhabdomyolysis and renal infarction case reports (Peters 2020); no human data in this group.
  • Adolescents: Inferred from a teenager’s rapid mole changes (Sivyer 2012); no controlled data in this group.

Risk Mitigation Strategies

Doses, timings and thresholds below follow common practice unless cited.

  • Baseline skin examination with mole mapping: A full-body dermatology exam with dermoscopic (magnified skin-surface) photographs before the first dose, repeated every 6 months, detects new or changing moles and melanoma early; setmelanotide investigators advise regular skin exams (Kanti 2021).
  • Stopping on mole change: Any new, darkening, enlarging or irregular mole prompts stopping and dermatologic review, limiting delayed melanoma diagnosis (Cardones 2009 reports lightening after stopping).
  • Low starting dose: Trials started at 0.01 mg/kg and capped at 0.025 to 0.03 mg/kg (Dorr 1996), limiting nausea and drowsiness; a 6 mg overdose caused systemic toxicity (Nelson 2012).
  • Blood pressure checks: Readings 1–4 hours after early doses detect pressor responses; stage 2 hypertension (at least 140/90 mmHg), per a cardiology-society guideline whose members earn revenue treating hypertension (Whelton 2018), signals stopping, limiting cardiovascular and brain-swelling risk.
  • Priapism action threshold: An erection lasting more than 4 hours warrants emergency care, the threshold sildenafil’s label sets for drug-induced erections (Viagra label), limiting permanent erectile tissue damage.
  • No PDE5 inhibitors on dosing days: Separating them by at least 24 hours lowers additive priapism risk.
  • No sunbeds: Avoiding added UV exposure limits combined pigment-cell stimulation implicated in a melanoma case (Hjuler 2014).
  • Sterile, unshared injection equipment: Single-use needles and personal vials prevent bloodborne virus transmission and infection, risks a dermatology review highlights (Langan 2010).
  • Independent identity and purity testing: Mass-spectrometry (molecular-weight analysis) testing of each batch reduces under-dosing and impurity exposure (Breindahl 2015).
  • Muscle and urine vigilance: Severe muscle pain or dark urine after dosing prompts stopping and a creatine kinase test, catching rhabdomyolysis early (Nelson 2012).

Therapeutic Protocol

Parameters other than doses (e.g., timing, cycling, titration (stepwise dose increase) steps) reflect common practice unless cited.

  • No validated longevity protocol: No trial has tested Melanotan II for health or longevity outcomes; regimens derive from 1990s trials and online forums (Gilhooley 2021).
  • Trial tanning regimen: Subcutaneous (under-the-skin) injections every other day for 2 weeks, starting at 0.01 mg/kg and rising in 0.005 mg/kg steps; 0.025 mg/kg per day was the recommended dose (Dorr 1996).
  • Trial erectile regimen: A single 0.025 mg/kg subcutaneous injection, without sexual stimulation, with effects tracked over 6 hours (Wessells 1998, Wessells 2000).
  • Gray-market regimens: Forum users describe self-devised dosing schedules, often combined with sunbed sessions (Gilhooley 2021); actual vial content varies (Breindahl 2015).
  • Approved alternatives: Afamelanotide 16 mg implants every 60 days for a light-sensitivity disorder (Langendonk 2015); bremelanotide 1.75 mg as needed for low desire in premenopausal women (Kingsberg 2019).
  • Who popularized it: The University of Arizona group of Hadley, Hruby and Dorr developed the trial regimens, per their review (Hadley 2006); online sellers and forums popularized self-injection, per an editorial (Evans-Brown 2009).
  • Time of day: Trials did not test timing; evening dosing is common so nausea and drowsiness pass during sleep, at the cost of possible night-time erections.
  • Half-life: No human half-life is published; erections lasted 1 to 5 hours after dosing (Dorr 1996), and analogue bremelanotide’s half-life is 2.7 hours (Vyleesi label).
  • Single vs split dosing: Trials used one injection per day; split dosing is untested.
  • Genetic polymorphisms: MC1R variants may amplify pigment response (Fitzgerald 2006, afamelanotide); no pharmacogenetic (gene-guided) dosing data exist.
  • Sex differences: All Melanotan II dosing data are from men; women have no tested dose.
  • Age: No dose data exist for older adults; slower titration is common practice for them.
  • Baseline biomarkers: Baseline blood pressure and mole count shape whether, and how cautiously, dosing proceeds.
  • Pre-existing conditions: Cardiovascular disease, kidney disease and melanoma history change the risk side of any dose decision (see Populations who should avoid).

Discontinuation & Cycling

  • Short-term, not lifelong: The longest controlled exposure was 2 weeks (Dorr 1996); no data support long-term use.
  • Withdrawal effects: None are reported; eruptive moles lightened and stopped growing after use ended in one case (Cardones 2009).
  • Tapering: No tapering protocol has been studied; given its hours-long action, abrupt stopping is standard.
  • Agents stopped together: Not applicable; Melanotan II is a single agent.
  • Cycling and tolerance: In rats, appetite suppression faded within 5 days of continuous dosing and returned after an off period (Zhang 2010); human cycling schedules for tanning maintenance are unvalidated.
  • Persistent pigment changes: Lentigines and focal darkening may outlast use; for bremelanotide, resolution was not confirmed in some patients (Vyleesi label).

Sourcing and Quality

  • No licensed source: Melanotan II is not an approved medicine; the FDA lists it among bulk substances once placed in its “significant safety risks” category whose compounding nomination was later withdrawn (FDA Category 2 page).
  • Measured content and purity: Online vials contained 4.32 to 8.84 mg against a labeled 10 mg, with 4.1 to 5.9% unknown impurities in two of three shops (Breindahl 2015).
  • Black-market products: Unknown samples seized with bodybuilding drugs contained Melanotan II or bremelanotide, which a forensic laboratory characterized by high-resolution mass spectrometry without reference standards (Mestria 2021).
  • What testing can and cannot show: Identity and purity certificates do not establish sterility, endotoxin (bacterial toxin) levels or aggregation (peptide clumping); the FDA links aggregation and peptide-related impurities to immunogenicity (FDA Category 2 page).
  • Formulation: Sold as freeze-dried powder for reconstitution and subcutaneous injection; products labeled “melanotan” may contain Melanotan I or II, a dermatology review notes (Langan 2010).
  • Reputable brands or pharmacies: None can be named; no manufacturer or compounding pharmacy supplies Melanotan II under regulatory oversight.

Practical Considerations

  • Time to effect: Erections began within hours and lasted 1 to 5 hours; visible pigmentation appeared within about 1 week after five doses (Dorr 1996).
  • Common pitfalls: Combining injections with sunbeds (Hjuler 2014), escalating to multiples of usual doses (Nelson 2012), sharing needles, confusing Melanotan I and II, and ignoring changing moles.
  • Regulatory status (United States): Not approved; the FDA’s Pharmacy Compounding Advisory Committee plans to review Melanotan II for the compounding bulks list at a meeting before the end of February 2027 (FDA advisory committee page).
  • Regulatory status (elsewhere): No regulator has authorised it; several national health organizations, including the UK Medicines and Healthcare products Regulatory Agency, have issued safety warnings, as two dermatology reviews report (Habbema 2017, Langan 2010).
  • Cost and access: Gray-market vials are inexpensive and easy to buy online but legally unobtainable through pharmacies; generic erectile dysfunction medications and sunscreen are cheap, so insurers and health systems have no financial incentive to fund Melanotan II research.
  • Research incentives: With development shifted to bremelanotide, as the developers’ review recounts (Hadley 2006), no company funds Melanotan II safety studies, a structural gap in the evidence.

Interaction with Foundational Habits

  • Sleep: Direct, potentially disruptive. Drowsiness and fatigue occurred at 0.03 mg/kg (Dorr 1996), and evening dosing can bring nausea and spontaneous erections into the night; logging sleep quality during the first doses reveals individual effects.
  • Nutrition: Direct, appetite-blunting through MC4R activation; decreased appetite and nausea were reported in trials (Wessells 1998). A small meal before dosing and protein-adequate intake help preserve lean mass during reduced eating; no nutrient depletion is known.
  • Exercise: Indirect. Sympathetic activation can raise heart rate and blood pressure (Nelson 2012); intense training soon after dosing and dehydration plausibly compound rhabdomyolysis risk (inferred). Bodybuilders often use it before competitions (Gilhooley 2021).
  • Stress management: Indirect, potentiating. Overdose produced anxiety and agitation (Nelson 2012), and appearance-driven use has been linked to body dysmorphic disorder (preoccupation with perceived flaws) (Affleck 2010); attention to motivation and mood supports safer decisions.

Monitoring Protocol & Defining Success

Baseline testing before any use establishes a reference point: a full-body dermatology examination with dermoscopic mole photographs, seated blood pressure and resting heart rate, and blood and urine tests for muscle and kidney injury, plus standardized skin photographs and body weight to track expected changes.

Ongoing monitoring follows this cadence: blood pressure and heart rate before and 1 to 4 hours after each of the first three doses, laboratory tests at 4 weeks, a dermatology examination every 6 months during use, and a final skin check 3 months after stopping. Laboratory tests are repeated sooner with muscle pain, dark urine, headache or visual change. Success means the intended pigment or sexual-function change without new or changing moles, sustained blood pressure rises, or laboratory abnormalities.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Blood pressure Below 120/80 mmHg (normal, ACC/AHA 2017 guideline) Safety check: rises signal pressor response; stop at 140/90 mmHg or above ACC/AHA: American College of Cardiology/American Heart Association (Whelton 2018), whose members earn revenue treating hypertension; conventional reference range: systolic below 120, diastolic below 80 mmHg; seated, after 5 minutes’ rest
Resting heart rate 60–100 beats per minute (standard reference range) Safety check: tachycardia suggests sympathetic overactivation Measure with blood pressure; tachycardia = fast heart rate
Creatine kinase About 20–200 U/L, laboratory-specific (standard reference range) Safety check: elevation signals muscle breakdown Avoid strenuous exercise 48 hours before testing; U/L = units per liter
Serum creatinine with eGFR Creatinine about 0.7–1.3 mg/dL in men, 0.6–1.1 mg/dL in women (standard reference range) Safety check: rise signals kidney injury eGFR (estimated glomerular filtration rate, a calculated kidney-filtration measure) is tracked against the individual’s own baseline
Urinalysis for blood Negative (standard reference range) Safety check: positive blood with few red cells suggests muscle-protein spillage Pair with creatine kinase
Mole count and dermoscopic images No established target; track new or changing moles against baseline photographs Safety check: new atypical moles stop use Dermoscopy = magnified skin-surface imaging; same lighting and positions each visit
Skin pigmentation (standardized photographs) No established target; track change from the individual’s baseline Expected to change: darkening shows response Same camera, lighting and body sites
Body weight No established target; track change from the individual’s baseline Expected to change: appetite reduction may lower weight Morning, fasted, same scale

Qualitative markers:

  • Nausea severity and duration after each dose
  • Drowsiness, yawning and sleep quality
  • Spontaneous erections, their duration, and any lasting more than 4 hours
  • Sexual desire and appetite changes
  • New, darkening or irregular moles, freckles or nail lines
  • Headache, visual disturbance or confusion (possible brain swelling)
  • Muscle pain or dark urine

Emerging Research

  • Melanotan II with light therapy for vitiligo (patchy loss of skin pigment) (NCT07437560): Recruiting phase 2, 60 adults, Melanotan II or placebo plus narrowband ultraviolet B, primary endpoint 24-week vitiligo score change; the record calls itself an “example.” A positive result would add independent placebo-controlled pigment data; a null result would weaken pigmentation claims.
  • FDA compounding review: The FDA advisory committee will consider Melanotan II for the compounding bulks list before the end of February 2027 (FDA advisory committee page); its briefing could compile safety data not yet public.
  • Afamelanotide with light therapy for vitiligo (NCT06109649): Phase 3, 200 patients, Clinuvel-sponsored; registered completion June 2026, status active, not recruiting, no results posted. A positive result would strengthen pigment-efficacy data for a related MC1R agonist; a null result, or frequent new moles, would weaken the case for melanocortin-driven tanning.
  • Oral MC1R agonist dersimelagon (NCT05005975): Ongoing phase 3 long-term extension, 286 patients with light-sensitivity disorders, tracking adverse events and new moles through 2027. Few new moles would ease concerns about melanocortin-driven mole growth; frequent moles would strengthen them.
  • Bremelanotide plus tirzepatide for obesity (NCT06565611): Phase 2, registry status active, not recruiting, estimated completion March 2025; no registry results; company-reported 4.4% vs 1.6% weight loss with placebo at 8 weeks (Palatin press release).
  • Long-term melanoma risk: No cohort has measured melanoma incidence in users; a systematic case review could not assess malignant transformation risk (Burian 2019), leaving the central safety question open in either direction.
  • Brain health: Melanocortin activation reduced amyloid and inflammation in mice (Lau 2021); human studies would be needed before any longevity relevance could be judged.

Conclusion

Melanotan II is an unapproved, self-injected copy of the body’s pigment hormone that also acts in the brain. For health-focused adults, its appeal rests on three effects: a darker skin tone without sunlight, stronger erections and desire in men, and reduced appetite.

The direct human evidence is thin. Small, short trials run by the scientists who invented and patented the compound suggest that it triggers erections and increases desire in men with erectile dysfunction, and that it can darken skin. Benefits that would matter for long-term health, such as protection against sun damage or weight loss, are inferred from related approved drugs rather than shown for Melanotan II itself, and brain-protective effects exist only in animals. No study has looked at lifespan or aging outcomes.

The harm side is also built mostly from scattered reports, but the reported events are serious: new and changing moles, melanomas, painful prolonged erections needing emergency treatment, muscle breakdown with kidney injury, and a dangerous brain-swelling syndrome. Nausea and drowsiness are common. Products bought online often contain less drug than labeled plus unknown impurities, and no regulated source exists.

Overall, the evidence base is small, old, shaped by the developers’ financial interest, and contains no long-term safety data, which carry the most weight in a longevity frame. The uncertainty runs in both directions, and the most consequential question, long-term melanoma risk, remains open.

Top - Benefits - Risks - Protocol